Business Context and Reporting Period
Company: Abbott Laboratories (ABT)
Filing Type: Form 8-K (Current Report)
Date of Report: November 12, 2024
Subject: Extension of Change in Control Agreements for Named Executive Officers.
Key Financial Metrics
This filing does not contain financial performance data. No revenue, profit, cash flow, margin, debt, or liquidity metrics are reported in this document.
Material Changes
The filing reports a material change regarding executive compensation arrangements:
- Abbott Laboratories notified its named executive officers on November 12, 2024, that their Agreements Regarding Change in Control were extended.
- The original expiration date of December 31, 2024, has been extended through December 31, 2026.
- This extension applies if Abbott provides notification before the original expiration date, as per the agreement terms.
Guidance, Outlook, and Risks
This filing contains no forward-looking guidance, management commentary on business outlook, or discussion of new risks or contingencies. The document is strictly procedural regarding the extension of executive agreements.
Investor Verification Checklist
- Verify the specific terms of the Change in Control Agreements for named executive officers in prior filings (e.g., Proxy Statements).
- Confirm the list of named executive officers covered by the extension.
- Review the impact of the extended agreements on potential severance or retention costs in the event of a change in control between 2025 and 2026.